Formula: | C16H10ClN3O5 |
Molecular Weight: | 359.73 |
Rotatable Bond Donors: | 4 |
clogP: | 2.43 |
Topological Polar Surface Area: | 121.57 |
Lipinski's RO5: | MW: 359.73 HBA: 8 HBD: 3 RB: 4 LogP: 2.43 |
Rule of Three: | MW: 359.73 HBA: 8 HBD: 3 RB: 4 LogP: 2.43 |
|
DB |
---|
ZINC ID | Similarity | Structure | SDF |
---|
ZINC ID | Similarity | Structure | SDF | |
---|---|---|---|---|
ZINC2526465 | 1.0 | ZINC2526465 RDKit 3D 25 27 0 0 0 0 0 0 0 0999 V2000 0.9572 -0.0117 -2.9999 O 0 0 0 0 0 0 0 0 0 0 0 0 -0.0484 -0.3655 -2.4069 C 0 0 0 0 0 0 0 0 0 0 0 0 -1.1454 -0.9672 -2.9411 N 0 0 0 0 0 0 0 0 0 0 0 0 -2.0816 -1.1562 -1.9767 C 0 0 0 0 0 0 0 0 0 0 0 0 -3.1794 -1.6756 -2.0830 O 0 0 0 0 0 0 0 0 0 0 0 0 -1.5403 -0.6232 -0.7138 C 0 0 0 0 0 0 0 0 0 0 0 0 -2.2523 -0.6163 0.5618 C 0 0 0 0 0 0 0 0 0 0 0 0 -2.5126 -1.8632 1.1414 C 0 0 0 0 0 0 0 0 0 0 0 0 -3.1573 -1.9695 2.3737 C 0 0 0 0 0 0 0 0 0 0 0 0 -3.5532 -0.8224 3.0545 C 0 0 0 0 0 0 0 0 0 0 0 0 -3.3137 0.4299 2.4996 C 0 0 0 0 0 0 0 0 0 0 0 0 -2.6712 0.5261 1.2625 C 0 0 0 0 0 0 0 0 0 0 0 0 -2.4922 1.8680 0.7327 N 0 0 0 0 0 4 0 0 0 0 0 0 -2.2485 2.7711 1.5426 O 0 0 0 0 0 0 0 0 0 0 0 0 -2.5941 2.0178 -0.4927 O 0 0 0 0 0 1 0 0 0 0 0 0 -0.2949 -0.1918 -0.9507 C 0 0 0 0 0 0 0 0 0 0 0 0 0.5931 0.4035 -0.0849 N 0 0 0 0 0 0 0 0 0 0 0 0 1.9929 0.2169 -0.0832 C 0 0 0 0 0 0 0 0 0 0 0 0 2.6104 -0.9125 -0.6314 C 0 0 0 0 0 0 0 0 0 0 0 0 3.9931 -1.0733 -0.5720 C 0 0 0 0 0 0 0 0 0 0 0 0 4.7668 -0.1053 0.0560 C 0 0 0 0 0 0 0 0 0 0 0 0 6.1165 -0.2932 0.1019 O 0 0 0 0 0 0 0 0 0 0 0 0 4.1728 1.0157 0.6247 C 0 0 0 0 0 0 0 0 0 0 0 0 5.0927 2.2282 1.4255 Cl 0 0 0 0 0 0 0 0 0 0 0 0 2.7897 1.1699 0.5593 C 0 0 0 0 0 0 0 0 0 0 0 0 1 2 2 0 2 3 1 0 3 4 1 0 4 5 2 0 4 6 1 0 6 7 1 0 7 8 2 0 8 9 1 0 9 10 2 0 10 11 1 0 11 12 2 0 12 13 1 0 13 14 2 0 13 15 1 0 6 16 2 0 16 17 1 0 17 18 1 0 18 19 2 0 19 20 1 0 20 21 2 0 21 22 1 0 21 23 1 0 23 24 1 0 23 25 2 0 16 2 1 0 25 18 1 0 12 7 1 0 M CHG 2 13 1 15 -1 M END $$$$ |
Name | Assay stage | Target | Activity |
---|---|---|---|
Single dose inhibition of SARS-CoV-2 cytopathic effect in VeroE6 | primary assay | Organism Severe acute respiratory syndrome-related coronavirus | inactive |
Single dose inhibition of SARS-CoV-2 3CL-Pro | primary assay | Replicase polyprotein 1ab | inactive |